Landshut\/ Martins\u00adried \u2014 High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF), Crea\u00adthor Ventures, KfW and Bayern Kapi\u00adtal have announ\u00adced to sell their invest\u00adment in SIRION Biotech GmbH, an inter\u00adna\u00adtio\u00adnal provi\u00adder of viral vector tech\u00adno\u00adlo\u00adgies for the effi\u00adci\u00adent deve\u00adlo\u00adp\u00adment and deli\u00advery of cell and gene thera\u00adpies. SIRI\u00adON\u2019s services ideally comple\u00adment Perki\u00adnEl\u00admer\u2019s Hori\u00adzon Disco\u00advery port\u00adfo\u00adlio, it says. The tran\u00adsac\u00adtion is still subject to regu\u00adla\u00adtory approvals.<\/p>\n
For its part, Perki\u00adnEl\u00admer, Inc, a U.S. chemi\u00adcal and medi\u00adcal tech\u00adno\u00adlogy company, has announ\u00adced that it has reached an agree\u00adment to acquire SIRION. The tran\u00adsac\u00adtion is expec\u00adted to close in the third quar\u00adter of 2021. In 2007, Crea\u00adthor Ventures, HTGF, Bayern Kapi\u00adtal and KfW jointly inves\u00adted in SIRION as part of a seed finan\u00adcing round.<\/p>\n
Head\u00adquar\u00adte\u00adred in Martins\u00adried near Munich, SIRION has a total of 50 employees at loca\u00adti\u00adons in Germany, France and the USA. The company has built a robust port\u00adfo\u00adlio of licen\u00adsed vector tech\u00adno\u00adlo\u00adgies that are used by more than a dozen major phar\u00admaceu\u00adti\u00adcal and biotech compa\u00adnies that are inves\u00adti\u00adga\u00adting a total of more than 25 diffe\u00adrent diseases.<\/p>\n
\u201cOur team looks forward to working with Perki\u00adnEl\u00admer as we conti\u00adnue to expand our leader\u00adship posi\u00adtion in viral vector tech\u00adno\u00adlo\u00adgies for cell and gene therapy. As part of Perki\u00adnEl\u00admer, we will bene\u00adfit from faci\u00adli\u00adta\u00adted access to geno\u00admic analy\u00adsis, gene editing and base editing tech\u00adno\u00adlo\u00adgies, as well as excel\u00adlent global infra\u00adstruc\u00adture and presence,\u201d said Dr. Chris\u00adtian Thirion, CEO of SIRION<\/strong>.<\/p>\n \u201cWe are very proud to have accom\u00adpa\u00adnied the successful deve\u00adlo\u00adp\u00adment of SIRION. As a seed inves\u00adtor, we are always on the lookout for tech\u00adno\u00adlo\u00adgies where great poten\u00adtial can be seen even before market entry, as well as for highly moti\u00adva\u00adted foun\u00adders and teams. All of this applied to SIRION,\u201d says Marco Winzer, Part\u00adner at HTGF<\/strong>.<\/p>\n \u201cSIRION is an excel\u00adlent exam\u00adple of how foun\u00adders and manage\u00adment teams can deve\u00adlop an inno\u00adva\u00adtive tech\u00adno\u00adlogy from early stage in the lab to inter\u00adna\u00adtio\u00adnal tech\u00adno\u00adlogy leader\u00adship toge\u00adther with expe\u00adri\u00aden\u00adced inves\u00adtors. We are very plea\u00adsed to have played an active role in this success story,\u201d says Karl\u00adheinz Schme\u00adlig, Part\u00adner at Crea\u00adthor Ventures<\/strong>.<\/p>\n \u201cWe were very impres\u00adsed by SIRI\u00adON\u2019s tech\u00adni\u00adcal and market exper\u00adtise right from the start and have actively supported the company from the begin\u00adning. We are ther\u00ade\u00adfore very plea\u00adsed about this great success and wish SIRION all the best,\u201d says Roman Huber, Mana\u00adging Direc\u00adtor at Bayern Kapi\u00adtal<\/strong>.<\/p>\n About SIRION Biotech GmbH<\/strong> About Crea\u00adthor Ventures<\/strong> About High-Tech Gr\u00fcnderfonds<\/strong> About KfW<\/strong> KfW does not have any bran\u00adches and does not have any custo\u00admer depo\u00adsits. It refi\u00adnan\u00adces its promo\u00adtio\u00adnal busi\u00adness respon\u00adsi\u00adbly and almost enti\u00adrely via the inter\u00adna\u00adtio\u00adnal capi\u00adtal markets. In 2020, it borro\u00adwed EUR 66.4 billion for this purpose. It employs more than 6,700 people at its head\u00adquar\u00adters in Frank\u00adfurt am Main, its two bran\u00adches in Berlin and Bonn, and its subsi\u00addia\u00adries KfW IPEX-Bank, DEG and KfW Capi\u00adtal. It is repre\u00adsen\u00adted at around 80 loca\u00adti\u00adons world\u00adwide. www.kfw.de<\/p>\n About Bayern Kapital<\/strong> Landshut\/ Martins\u00adried \u2014 High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF), Crea\u00adthor Ventures, KfW and Bayern Kapi\u00adtal have announ\u00adced to sell their invest\u00adment in SIRION Biotech GmbH, an inter\u00adna\u00adtio\u00adnal provi\u00adder of viral vector tech\u00adno\u00adlo\u00adgies for the effi\u00adci\u00adent deve\u00adlo\u00adp\u00adment and deli\u00advery of cell and gene thera\u00adpies. SIRI\u00adON\u2019s services ideally comple\u00adment Perki\u00adnEl\u00admer\u2019s Hori\u00adzon Disco\u00advery port\u00adfo\u00adlio, it says. The tran\u00adsac\u00adtion is still subject [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":37600,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1365,1366,1369,1372],"tags":[],"class_list":["post-43555","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-private-equity-en","category-news-en","category-investors","category-consultant"],"yoast_head":"\n
\nSIRION Biotech was foun\u00added in 2005 with the goal of deve\u00adlo\u00adping a new gene\u00adra\u00adtion of viral vector tech\u00adno\u00adlo\u00adgies for gene and cell therapy and vaccine deve\u00adlo\u00adp\u00adment. SIRION deve\u00adlops novel thera\u00adpeu\u00adtic viral vectors and lever\u00ada\u00adges proprie\u00adtary tech\u00adno\u00adlogy plat\u00adforms based on lenti\u2011, adeno- and adeno-asso\u00adcia\u00adted viru\u00adses to acce\u00adle\u00adrate its part\u00adners\u2019 progress in drug deve\u00adlo\u00adp\u00adment. www.sirion-biotech.com.<\/p>\n
\nCrea\u00adthor Ventures invests in tech\u00adno\u00adlogy-driven compa\u00adnies that are advan\u00adcing the auto\u00adma\u00adtion of indus\u00adtry and busi\u00adness, as well as the perso\u00adna\u00adliza\u00adtion and digi\u00adtiza\u00adtion of health\u00adcare. The team curr\u00adently mana\u00adges over 30 tech and health\u00adcare compa\u00adnies and has funded over 200 compa\u00adnies as a lead or co-lead inves\u00adtor over the past 30 years. More than 20 compa\u00adnies were listed on inter\u00adna\u00adtio\u00adnal stock exch\u00adan\u00adges. Crea\u00adthor Ventures curr\u00adently mana\u00adges a fund volume of over 230 million euros. www.creathor.com<\/p>\n
\nThe seed inves\u00adtor High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF) finan\u00adces tech\u00adno\u00adlogy start-ups with growth poten\u00adtial. With a volume of around EUR 900 million spread across three funds and an inter\u00adna\u00adtio\u00adnal part\u00adner network, HTGF has supported more than 600 start-ups since 2005. His team of expe\u00adri\u00aden\u00adced invest\u00adment mana\u00adgers and start-up experts supports the young compa\u00adnies with know-how, entre\u00adpre\u00adneu\u00adrial spirit and passion. The focus is on high-tech start-ups in the fields of digi\u00adtal tech, indus\u00adtrial tech, life scien\u00adces, chemis\u00adtry and rela\u00adted busi\u00adness areas. More than EUR 3 billion in capi\u00adtal has been inves\u00adted in the HTGF port\u00adfo\u00adlio by exter\u00adnal inves\u00adtors in more than 1,700 follow-on finan\u00adcing rounds to date. In addi\u00adtion, the fund has alre\u00adady successfully sold shares in more than 130 compa\u00adnies. www.htgf.de<\/p>\n
\nKfW is one of the worl\u00add\u2019s leading promo\u00adtio\u00adnal banks. With its deca\u00addes of expe\u00adri\u00adence, KfW works on behalf of the German fede\u00adral and state govern\u00adments to improve econo\u00admic, social and ecolo\u00adgi\u00adcal living condi\u00adti\u00adons world\u00adwide. In 2020 alone, it has made a funding volume of EUR 135.3 billion available for this purpose. Of this, 33% was spent on climate and envi\u00adron\u00admen\u00adtal protec\u00adtion measures.<\/p>\n
\nBayern Kapi\u00adtal GmbH, based in Lands\u00adhut, was foun\u00added in 1995 as a wholly owned subsi\u00addiary of LfA F\u00f6rder\u00adbank Bayern on the initia\u00adtive of the Bava\u00adrian state govern\u00adment. As the venture capi\u00adtal company of the Free State of Bava\u00adria, Bayern Kapi\u00adtal provi\u00addes equity capi\u00adtal to the foun\u00adders of inno\u00adva\u00adtive high-tech compa\u00adnies and young, inno\u00adva\u00adtive tech\u00adno\u00adlogy compa\u00adnies in Bava\u00adria. Bayern Kapi\u00adtal curr\u00adently mana\u00adges twelve invest\u00adment funds with an invest\u00adment volume of around 500 million euros. To date, Bayern Kapi\u00adtal has inves\u00adted around 350 million euros of venture capi\u00adtal in around 290 inno\u00adva\u00adtive tech\u00adno\u00adlogy-orien\u00adted compa\u00adnies from a wide range of sectors, inclu\u00adding life scien\u00adces, soft\u00adware & IT, mate\u00adri\u00adals & new mate\u00adri\u00adals, nano\u00adtech\u00adno\u00adlogy and envi\u00adron\u00admen\u00adtal tech\u00adno\u00adlogy. As a result, more than 8,000 jobs have been perma\u00adnently crea\u00adted in Bava\u00adria in sustainable compa\u00adnies. www.bayernkapital.de<\/p>\n","protected":false},"excerpt":{"rendered":"